MA50455A - Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur - Google Patents
Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleurInfo
- Publication number
- MA50455A MA50455A MA050455A MA50455A MA50455A MA 50455 A MA50455 A MA 50455A MA 050455 A MA050455 A MA 050455A MA 50455 A MA50455 A MA 50455A MA 50455 A MA50455 A MA 50455A
- Authority
- MA
- Morocco
- Prior art keywords
- pain
- alcoxyamino
- derivatives
- associated conditions
- pain associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382721 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50455A true MA50455A (fr) | 2021-06-02 |
Family
ID=60262875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050455A MA50455A (fr) | 2017-10-27 | 2018-10-26 | Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11401270B2 (fr) |
| EP (1) | EP3700890B1 (fr) |
| JP (1) | JP2021500416A (fr) |
| KR (1) | KR20200097694A (fr) |
| CN (1) | CN111566091A (fr) |
| AR (1) | AR113799A1 (fr) |
| AU (1) | AU2018356556A1 (fr) |
| BR (1) | BR112020008371A2 (fr) |
| CA (1) | CA3084425A1 (fr) |
| ES (1) | ES2905582T3 (fr) |
| IL (1) | IL274254A (fr) |
| MA (1) | MA50455A (fr) |
| MX (1) | MX2020003575A (fr) |
| PH (1) | PH12020550594A1 (fr) |
| PT (1) | PT3700890T (fr) |
| RU (1) | RU2020114523A (fr) |
| SG (1) | SG11202003599UA (fr) |
| TW (1) | TW201925179A (fr) |
| WO (1) | WO2019081691A1 (fr) |
| ZA (1) | ZA202002526B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021553058A1 (en) | 2019-06-06 | 2022-07-25 | Hutchison Medipharma Ltd | Tricyclic compounds and their use |
| SMT202500238T1 (it) * | 2021-01-29 | 2025-07-22 | 3Z Ehf | Composti per l’uso nel trattamento di disturbo da iperattività e deficit di attenzione |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3702755A1 (de) * | 1987-01-30 | 1988-08-11 | Hoechst Ag | 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung |
| CA2497979A1 (fr) * | 2002-09-06 | 2004-03-18 | Elan Pharmaceuticals, Inc. | Derives de promedicaments a base de 1, 3-diamino-2-hydroxypropane |
| PE20050068A1 (es) * | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
| US7569604B2 (en) * | 2004-06-22 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives for modulation of calcium channels |
| EP1820799A1 (fr) * | 2004-11-10 | 2007-08-22 | Wakamoto Pharmaceutical Co., Ltd. | Dérivé de 2,3,4,5-tétrahydro-1h-1,5-benzodiazépine et préparation thérapeutique |
| WO2008073929A1 (fr) * | 2006-12-11 | 2008-06-19 | Wyeth | Modulateurs de canal ionique |
| TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| MY196791A (en) * | 2016-05-06 | 2023-05-03 | Esteve Pharmaceuticals Sa | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions |
| WO2019076904A1 (fr) * | 2017-10-16 | 2019-04-25 | Esteve Pharmaceuticals, S.A. | Dérivés de propanamine destinés au traitement de la douleur et des états pathologiques associés à la douleur |
-
2018
- 2018-10-26 JP JP2020543717A patent/JP2021500416A/ja active Pending
- 2018-10-26 AR ARP180103121A patent/AR113799A1/es unknown
- 2018-10-26 MX MX2020003575A patent/MX2020003575A/es unknown
- 2018-10-26 MA MA050455A patent/MA50455A/fr unknown
- 2018-10-26 WO PCT/EP2018/079367 patent/WO2019081691A1/fr not_active Ceased
- 2018-10-26 CA CA3084425A patent/CA3084425A1/fr not_active Abandoned
- 2018-10-26 BR BR112020008371-2A patent/BR112020008371A2/pt not_active Application Discontinuation
- 2018-10-26 KR KR1020207015088A patent/KR20200097694A/ko not_active Withdrawn
- 2018-10-26 SG SG11202003599UA patent/SG11202003599UA/en unknown
- 2018-10-26 CN CN201880069540.1A patent/CN111566091A/zh active Pending
- 2018-10-26 AU AU2018356556A patent/AU2018356556A1/en not_active Abandoned
- 2018-10-26 RU RU2020114523A patent/RU2020114523A/ru unknown
- 2018-10-26 PT PT188000582T patent/PT3700890T/pt unknown
- 2018-10-26 US US16/755,992 patent/US11401270B2/en active Active
- 2018-10-26 ES ES18800058T patent/ES2905582T3/es active Active
- 2018-10-26 EP EP18800058.2A patent/EP3700890B1/fr active Active
- 2018-10-26 TW TW107138004A patent/TW201925179A/zh unknown
-
2020
- 2020-04-24 PH PH12020550594A patent/PH12020550594A1/en unknown
- 2020-04-26 IL IL274254A patent/IL274254A/en unknown
- 2020-05-07 ZA ZA2020/02526A patent/ZA202002526B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200097694A (ko) | 2020-08-19 |
| CN111566091A (zh) | 2020-08-21 |
| US20200299297A1 (en) | 2020-09-24 |
| TW201925179A (zh) | 2019-07-01 |
| JP2021500416A (ja) | 2021-01-07 |
| CA3084425A1 (fr) | 2019-05-02 |
| IL274254A (en) | 2020-06-30 |
| SG11202003599UA (en) | 2020-05-28 |
| EP3700890B1 (fr) | 2021-11-17 |
| BR112020008371A2 (pt) | 2020-11-03 |
| AU2018356556A1 (en) | 2020-05-07 |
| MX2020003575A (es) | 2020-07-22 |
| PT3700890T (pt) | 2022-02-02 |
| EP3700890A1 (fr) | 2020-09-02 |
| WO2019081691A1 (fr) | 2019-05-02 |
| AR113799A1 (es) | 2020-06-10 |
| US11401270B2 (en) | 2022-08-02 |
| RU2020114523A (ru) | 2021-12-01 |
| ZA202002526B (en) | 2021-06-30 |
| ES2905582T3 (es) | 2022-04-11 |
| PH12020550594A1 (en) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271046A (en) | Compounds for treating huntington's disease | |
| EP3645014A4 (fr) | Système d'agents d'endormissement à action retard | |
| EP3734660A4 (fr) | Élément d'imagerie | |
| EP3426242A4 (fr) | Icaritine et dérivés d'icaritine | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3415071A4 (fr) | Système d'endoscope | |
| EP3437540A4 (fr) | Support d'endoscope | |
| FR3056393B1 (fr) | Orthese d'extension de machoires | |
| EP3609864C0 (fr) | Inhibiteurs de hdac6 et agents d'imagerie | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3303366A4 (fr) | Dérivés de dolastatine 10 et utilisations de ceux-ci | |
| IL268905B (en) | Phage therapy | |
| EP3618723A4 (fr) | Cathéter d'imagerie | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| EP3592377A4 (fr) | Formes posologiques de kallicréine tissulaire 1 | |
| EP3686204A4 (fr) | Dérivés de thiénodiazépine et leur application | |
| EP3624839A4 (fr) | Schémas posologiques d'immunoconjugués anti-cd33 | |
| EP3578955A4 (fr) | Système d'imagerie | |
| EP3632453A4 (fr) | Agent d'amélioration de la qualité musculaire | |
| MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
| EP3429569A4 (fr) | Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris | |
| EP3444345A4 (fr) | Dérivé d'arnmicro-143 | |
| EP3358825A4 (fr) | Élément d'imagerie, et endoscope | |
| MA50455A (fr) | Dérivés d'alcoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur | |
| EP3319980A4 (fr) | Formulations permettant d'améliorer l'efficacité des médicaments hydrophobes |